We have a very active program in experimental HIV medicine with major focus on gene engineering an HIV resistant immune system and exploring HIV latency and pathogenesis. Using all kinds of in vitro and in vivo methods, the ultimate goal is to provide a proof-of-clinical concept for future phase I clinical trials.
The laboratory of Dr. Speck is very well embedded in the research place of Zurich and benefits from its unique scientific richness. Notably, we have very active international collaborations for the gene engineering part (University of Pretoria (SA) and University of Geneva (CH)), for the HIV latency part (Institute of Human Genetics, Montpellier (FR)) and for the HIV pathogenesis part (Mount Sinai Hospital, New York (U.S.) and Weizmann Institute of Science, Israel).
The laboratory is well financed by various foundations, among others by the Swiss National Science Foundation, the Swiss South African Research Joint Program, the National Institute of Health, the Swiss Vaccine Institute, the Clinical Research Focus Program Human Hemato-Lymphatic Diseases of the University of Zurich